HomeCompareSCLTF vs JNJ

SCLTF vs JNJ: Dividend Comparison 2026

SCLTF yields 3210.27% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCLTF wins by $868001036828.74M in total portfolio value
10 years
SCLTF
SCLTF
● Live price
3210.27%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$868001036828.77M
Annual income
$817,883,765,700,886,400.00
Full SCLTF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SCLTF vs JNJ

📍 SCLTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCLTFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCLTF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCLTF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCLTF
Annual income on $10K today (after 15% tax)
$272,873.19/yr
After 10yr DRIP, annual income (after tax)
$695,201,200,845,753,500.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SCLTF beats the other by $695,201,200,845,749,500.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCLTF + JNJ for your $10,000?

SCLTF: 50%JNJ: 50%
100% JNJ50/50100% SCLTF
Portfolio after 10yr
$434000518414.40M
Annual income
$408,941,882,850,445,600.00/yr
Blended yield
94.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SCLTF
No analyst data
Altman Z
-31.4
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCLTF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCLTFJNJ
Forward yield3210.27%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$868001036828.77M$30.3K
Annual income after 10y$817,883,765,700,886,400.00$4,689.40
Total dividends collected$864548114577.74M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SCLTF vs JNJ ($10,000, DRIP)

YearSCLTF PortfolioSCLTF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$331,727$321,027.29$10,592$272.30+$321.1KSCLTF
2$10,307,613$9,952,664.60$11,289$357.73+$10.30MSCLTF
3$300,052,202$289,023,056.50$12,123$472.89+$300.04MSCLTF
4$8,184,040,627$7,862,984,770.50$13,141$629.86+$8184.03MSCLTF
5$209,192,410,129$200,435,486,658.76$14,408$846.81+$209192.40MSCLTF
6$5,011,999,515,282$4,788,163,636,443.06$16,021$1,151.60+$5011999.50MSCLTF
7$112,576,544,225,493$107,213,704,744,142.06$18,122$1,588.22+$112576544.21MSCLTF
8$2,371,083,350,433,164$2,250,626,448,111,885.50$20,930$2,228.20+$2371083350.41MSCLTF
9$46,838,571,147,553,416$44,301,511,962,589,930.00$24,792$3,191.91+$46838571147.53MSCLTF
10$868,001,036,828,768,500$817,883,765,700,886,400.00$30,274$4,689.40+$868001036828.74MSCLTF

SCLTF vs JNJ: Complete Analysis 2026

SCLTFStock

Searchlight Resources Inc., an exploration stage company, acquires, explores for, and develops mineral properties in Canada. It explores for copper, lead, cobalt, gold, vanadium, nickel, and uranium deposits, as well as rare earth elements. The company holds interests in the Kulyk Lake rare earth project located to the north La Ronge, Saskatchewan; the Bootleg Lake gold property located near Creighton, Saskatchewan; and the Duddridge Lake property located to the northwest of La Ronge, Saskatchewan. It also holds interests in the Flin Flon North project located in Saskatchewan; the Reef Lake nickel project located in north central Saskatchewan; and the Wapawekka Greenstone project located to western section of Wapawekka Greenstone Belt. In addition, it has an option to acquire a 100% interest in the Robinson Creek gold project located to the west of Creighton, Saskatchewan. The company was formerly known as Canyon Copper Corp. and changed its name to Searchlight Resources Inc. in July 2018. Searchlight Resources Inc. was incorporated in 2000 and is headquartered in Vancouver, Canada.

Full SCLTF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SCLTF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCLTF vs SCHDSCLTF vs JEPISCLTF vs OSCLTF vs KOSCLTF vs MAINSCLTF vs ABBVSCLTF vs MRKSCLTF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.